Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer
Completed
- Conditions
- Arthralgia
- Registration Number
- NCT03455907
- Lead Sponsor
- University Hospital, Lille
- Brief Summary
Self-administered questionnaire survey to determine the presence or absence of joint pain during bevacizumab treatment for lung, ovarian, colorectal cancers.
The principal end-point is the frequency of arthralgia after 6 months of treatment with Bevacizumab.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 71
Inclusion Criteria
- Patient with ovarian, colorectal or lung cancer receiving bevacizumab therapy
- Male or female (aged ≥18 years old)
- Performance Status (PS) between 0 and 2
- Expected life> 3 months
- Ability to answer a self-questionnaire
- Obtaining the non-opposition of patient participation
Exclusion Criteria
- Pregnant or lactating woman
- Rapid evolution of neoplastic pathology
- Major cognitive disorders that do not allow filling of the self-questionnaire
- Impossibility to submit to medical monitoring for social, psychological or geographical reasons
- Patients under guardianship or curatorship
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of arthralgia At 6 months Frequency of joint manifestations of any grade according to the CTCAE (Common Terminology Criteria for Adverse Events) scale version 4.0 observed between the start of bevacizumab treatment and 6 months of treatment.
- Secondary Outcome Measures
Name Time Method correlation between global cancer response and occurrence of arthralgia baseline, at 3 months, at 6 months auto questionnaire specific to the study Baseline at 3 months, at 6 months 16 questions concerning the location, intensity, management of joint pain
Trial Locations
- Locations (2)
Centre Oscar Lambret
🇫🇷Lille, France
Hôpital Huriez. CHRU
🇫🇷Lille, France